0001209191-20-008513.txt : 20200211
0001209191-20-008513.hdr.sgml : 20200211
20200211192110
ACCESSION NUMBER: 0001209191-20-008513
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200207
FILED AS OF DATE: 20200211
DATE AS OF CHANGE: 20200211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lloyd-Smith Malcolm
CENTRAL INDEX KEY: 0001557146
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 20599088
MAIL ADDRESS:
STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-07
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001557146
Lloyd-Smith Malcolm
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Regulatory Officer
Common Stock
2020-02-07
4
S
0
1015
103.2774
D
23200
D
Common Stock
2020-02-10
4
M
0
13042
32.99
A
36242
D
Common Stock
2020-02-10
4
S
0
13042
104.563
D
23200
D
Common Stock
2020-02-10
4
M
0
15927
81.49
A
39127
D
Common Stock
2020-02-10
4
S
0
15927
104.563
D
23200
D
Incentive Stock Option
32.99
2020-02-10
4
M
0
13042
0.00
D
2025-02-03
Common Stock
13042
0
D
Non-Qualified Stock Option
81.49
2020-02-10
4
M
0
15927
0.00
D
2028-02-05
Common Stock
15927
17596
D
Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.56 to $105.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted February 3, 2015 and vested monthly over four years.
Option granted February 5, 2018 and vests monthly over four years.
/s/ Darin Lippoldt, Attorney-in-Fact
2020-02-11